Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

BioXcel Therapeutics (BTAI) Net Margin (2022 - 2025)

BioXcel Therapeutics has reported Net Margin over the past 4 years, most recently at 5425.0% for Q4 2025.

  • Quarterly results put Net Margin at 5425.0% for Q4 2025, down 149003.0% from a year ago — trailing twelve months through Dec 2025 was 10150.62% (down 661942.0% YoY), and the annual figure for FY2025 was 10082.09%, down 656170.0%.
  • Net Margin for Q4 2025 was 5425.0% at BioXcel Therapeutics, up from 18739.8% in the prior quarter.
  • Over the last five years, Net Margin for BTAI hit a ceiling of 449600.0% in Q1 2022 and a floor of 30559.85% in Q3 2022.
  • Median Net Margin over the past 4 years was 8321.56% (2025), compared with a mean of 17124.11%.
  • Biggest five-year swings in Net Margin: plummeted -47494806bps in 2023 and later surged 2073930bps in 2024.
  • BioXcel Therapeutics' Net Margin stood at 22465.55% in 2022, then soared by 75bps to 5582.71% in 2023, then grew by 30bps to 3934.97% in 2024, then tumbled by -38bps to 5425.0% in 2025.
  • The last three reported values for Net Margin were 5425.0% (Q4 2025), 18739.8% (Q3 2025), and 16209.17% (Q2 2025) per Business Quant data.